Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2015 Sep;34(3):175-7.

Why admixture matters in genetically-guided therapy: missed targets in the COAG and EU-PACT trials

Jorge Duconge, Carmen L Cadilla, Richard L Seip, Gualberto Ruaño
Comment

Why admixture matters in genetically-guided therapy: missed targets in the COAG and EU-PACT trials

Jorge Duconge et al. P R Health Sci J. 2015 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing Interests Disclosures. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript, apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Figures

Figure 1
Figure 1
Percentage (%) of variance explained by covariates found to be significant predictors of warfarin dose variability in Puerto Ricans (i.e., genotypes, age, admixture, INR/dose on day 3 and amiodarone).
See this image and copyright information in PMC

Comment on

  • A pharmacogenetic versus a clinical algorithm for warfarin dosing.
    Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, Rosenberg YD, Eby CS, Madigan RA, McBane RB, Abdel-Rahman SZ, Stevens SM, Yale S, Mohler ER 3rd, Fang MC, Shah V, Horenstein RB, Limdi NA, Muldowney JA 3rd, Gujral J, Delafontaine P, Desnick RJ, Ortel TL, Billett HH, Pendleton RC, Geller NL, Halperin JL, Goldhaber SZ, Caldwell MD, Califf RM, Ellenberg JH; COAG Investigators. Kimmel SE, et al. N Engl J Med. 2013 Dec 12;369(24):2283-93. doi: 10.1056/NEJMoa1310669. Epub 2013 Nov 19. N Engl J Med. 2013. PMID: 24251361 Free PMC article. Clinical Trial.
  • A randomized trial of genotype-guided dosing of warfarin.
    Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, Kesteven P, Christersson C, Wahlström B, Stafberg C, Zhang JE, Leathart JB, Kohnke H, Maitland-van der Zee AH, Williamson PR, Daly AK, Avery P, Kamali F, Wadelius M; EU-PACT Group. Pirmohamed M, et al. N Engl J Med. 2013 Dec 12;369(24):2294-303. doi: 10.1056/NEJMoa1311386. Epub 2013 Nov 19. N Engl J Med. 2013. PMID: 24251363 Clinical Trial.

References

    1. Kimmel SE, French B, Kasner SE, et al. for the COAG Investigators A Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing. N Engl J Med. 2013;369:2283–2293. - PMC - PubMed
    1. Pirmohamed M, Burnside G, Eriksson N, et al. for the EU-PACT group A Randomized Trial of Genotype-Guided Dosing of Warfarin. N Engl J Med. 2013;369:2294–2303. - PubMed
    1. Johnson JA, Gong L, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing. Clin Pharmacol Ther. 2011;90:625–629. - PMC - PubMed
    1. Perera MA, Cavallari LH, Limdi NA, et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet. 2013;382:790–796. - PMC - PubMed
    1. Ruaño G, Duconge J, Windemuth A, et al. Physiogenomic analysis of the Puerto Rican population. Pharmacogenomics. 2009;10:565–577. - PMC - PubMed